Why the study?
The study was conducted to investigate the relationship between P2Y1 and P2Y12 genotypes and the risk of AMI, as well as ADP-induced platelet aggregation, in the Quanzhou population.
Are P2Y1 and P2Y12 polymorphisms associated with the risk of acute myocardial infarction and ADP-induced platelet aggregation?
Are P2Y1 and P2Y12 polymorphisms associated with the risk of acute myocardial infarction and ADP-induced platelet aggregation?
The P2Y12 H2 haplotype is associated with a significantly increased risk of acute myocardial infarction and may serve as a potential genetic marker for AMI risk.
Answers are grounded in this paper and cite their sources.
P2Y12 H2 haplotype may flag elevated AMI risk in select populations; leaves open any role in guiding therapy.
BACKGROUND: The objective of this study was to investigate the relationship between P2Y1 and P2Y12 genotypes and the risk of acute myocardial infarction (AMI) in the Quanzhou population and to determine associations between P2Y1 and P2Y12 genotypes and ADP-induced platelet aggregation in this population. METHODS: All subjects were screened for P2Y1 (c.1622A > G) and P2Y12 (H1/H2, c.34C > T) polymorphisms by direct DNA sequencing. The maximal platelet aggregation rate (MAR) in AMI patients (n = 61) and healthy control subjects (n = 50) was measured by a PL-12 platelet function analyzer, and adenosine diphosphate (ADP) (5 μmol/L) was used as an agonist. RESULTS: The haploid H2 allele in the P2Y12 gene was more frequent in patients with AMI than in control subjects (OR 1.887, P = 0.005). The P2Y12 H2 haplotype was significantly associated with AMI in the codominant (P = 0.008), dominant (OR 2.103, P = 0.003), and overdominant models (OR 2.133, P = 0.003). After adjusting for potential confounders, H2 haplotype carriers had a 2.132-fold increased risk for AMI (OR 2.132, P = 0.012) compared with noncarriers. Moreover, we observed that the ADP-induced MAR in the carriers of the H2 haplotype from the control group was somewhat higher than that in noncarriers of this group (P = 0.020). However, we failed to demonstrate that the P2Y1 H1/H2 polymorphism affected ADP-induced MAR in AMI patients. Additionally, P2Y1 c.1622A > and P2Y12 c.34C > T polymorphisms were not associated with the risk of AMI or ADP-induced MAR in either group. CONCLUSIONS: Therefore, our results suggest that the P2Y12 H2 haplotype was associated with a higher risk of AMI, while its effect on increased ADP-induced platelet aggregation remains to be investigated. Thus, the P2Y12 H2 haplotype may be a potential marker for AMI.
No takes yet. Share an insight, caveat, or question.
Su et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: